NeoPharm Croissance future

Future contrôle des critères 2/6

NeoPharm is forecast to grow earnings and revenue by 15.8% and 15% per annum respectively. EPS is expected to grow by 14.2% per annum. Return on equity is forecast to be 15.6% in 3 years.

Informations clés

15.8%

Taux de croissance des bénéfices

14.2%

Taux de croissance du BPA

Personal Products croissance des bénéfices	11.8%
Taux de croissance des recettes	15.0%
Rendement futur des capitaux propres	15.6%
Couverture par les analystes	Low
Dernière mise à jour	15 Oct 2024

Mises à jour récentes de la croissance future

Recent updates

NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some Investors

Sep 13

NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return Trends

Aug 07

NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Jun 13

How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?

Mar 02

We're Watching These Trends At NeoPharm (KOSDAQ:092730)

Feb 18

We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings

Feb 08

NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock

Jan 26

An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued

Jan 15

Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?

Jan 04

NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Dec 24

What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Dec 15

Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Dec 04

Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?

Nov 23

Prévisions de croissance des bénéfices et des revenus

KOSDAQ:A092730 - Estimations futures des analystes et données financières antérieures (KRW Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	157,300	33,750	35,700	35,700	2
12/31/2025	140,350	29,400	29,700	29,700	2
12/31/2024	120,200	24,700	23,000	23,000	1
6/30/2024	107,858	22,929	-3,941	17,678	N/A
3/31/2024	101,735	22,516	-1,808	20,105	N/A
12/31/2023	97,105	23,213	2,435	23,263	N/A
9/30/2023	92,271	20,733	22,967	24,024	N/A
6/30/2023	89,292	19,781	20,199	21,423	N/A
3/31/2023	86,272	18,912	18,966	19,685	N/A
12/31/2022	85,033	17,027	17,354	18,161	N/A
9/30/2022	86,805	18,245	17,373	18,071	N/A
6/30/2022	87,424	17,370	17,809	18,258	N/A
3/31/2022	87,321	16,905	18,775	19,267	N/A
12/31/2021	87,931	17,713	21,203	21,681	N/A
9/30/2021	86,802	18,207	20,320	20,881	N/A
6/30/2021	85,275	18,059	21,190	21,766	N/A
3/31/2021	85,287	18,474	18,837	19,464	N/A
12/31/2020	81,625	18,131	16,343	17,074	N/A
9/30/2020	81,413	18,734	11,309	17,364	N/A
6/30/2020	82,618	19,935	12,028	18,544	N/A
3/31/2020	82,680	19,901	16,909	24,255	N/A
12/31/2019	83,240	19,245	12,030	19,224	N/A
9/30/2019	79,611	18,002	15,245	17,190	N/A
6/30/2019	74,863	16,675	13,488	15,234	N/A
3/31/2019	69,500	15,795	10,168	12,149	N/A
12/31/2018	66,275	15,370	14,096	16,179	N/A
9/30/2018	63,143	13,682	11,351	13,893	N/A
6/30/2018	60,236	13,105	12,244	14,629	N/A
3/31/2018	57,175	12,514	N/A	12,814	N/A
12/31/2017	53,634	11,559	N/A	10,646	N/A
9/30/2017	49,765	9,814	N/A	10,212	N/A
6/30/2017	46,739	9,365	N/A	9,866	N/A
3/31/2017	43,164	8,096	N/A	9,548	N/A
12/31/2016	42,369	7,742	N/A	9,157	N/A
9/30/2016	43,097	5,955	N/A	8,664	N/A
6/30/2016	41,999	5,419	N/A	6,471	N/A
12/31/2015	35,965	3,407	N/A	6,095	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: A092730's forecast earnings growth (15.8% per year) is above the savings rate (2.6%).

Bénéfices vs marché: A092730's earnings (15.8% per year) are forecast to grow slower than the KR market (29.3% per year).

Croissance élevée des bénéfices: A092730's earnings are forecast to grow, but not significantly.

Chiffre d'affaires vs marché: A092730's revenue (15% per year) is forecast to grow faster than the KR market (9.9% per year).

Croissance élevée des revenus: A092730's revenue (15% per year) is forecast to grow slower than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: A092730's Return on Equity is forecast to be low in 3 years time (15.6%).

NeoPharm Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased to ₩46,333

Analysts lower EPS estimates to ₩2,091

Recent updates

New minor risk - Market cap size

Investor sentiment improves as stock rises 17%

NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some Investors

Second quarter 2024 earnings released: EPS: ₩752 (vs ₩699 in 2Q 2023)

NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return Trends

NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price

NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem

Full year 2023 earnings: EPS exceeds analyst expectations

Upcoming dividend of ₩700 per share at 2.9% yield

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 15%

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: ₩2,177 (vs ₩2,265 in FY 2021)

Now 20% undervalued

Upcoming dividend of ₩700 per share

Full year 2021 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ₩650 per share

Price target increased to ₩46,333

Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Full year 2020 earnings released: EPS ₩2,318 (vs ₩2,570 in FY 2019)

What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?

We're Watching These Trends At NeoPharm (KOSDAQ:092730)

We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings

NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock

An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued

Investor sentiment improved over the past week

New 90-day high: ₩29,500

Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?

NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Upcoming Dividend of ₩750 Per Share

What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?

Analysts lower EPS estimates to ₩2,091

New 90-day low: ₩27,250

New 90-day low - ₩28,000

New 90-day low - ₩30,000

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance